Trovagene Licenses Leukemia Marker to Quest Diagnostics | GenomeWeb

NEW YORK (GenomeWeb News) – Trovagene today said it has licensed to Quest Diagnostics non-exclusive rights to incorporate the nucleophosmin protein (NPM1) into its research and testing services for acute myelogenous leukemia.

The San Diego-based molecular diagnostics firm holds the exclusive worldwide rights to an issued US patent, as well as patent applications in the US and elsewhere, covering NPM. It has licensed non-exclusive rights to the marker to several diagnostic and lab testing firms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.